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among usual care group. In the unadjusted model, specialty care was associated
with lower risk of developing MS relapses with risk ratios (RR) of 0.813 for any
relapse, 0.765 for multiple relapses, hazard ratios (HR) of 0.727 for the first relapse,
0.782 for the second relapse. After adjusting for the demographics, socioeconom-
ics, comorbidities, and health services utilizations, specialty care was associated
with lower risk of MS relapses with RRs of 0.761 for any relapses, 0.712 for multiple
relapses; lower HRs of 0.674 for the first relapse, and of 0.741 for the second relapse,
compared to usual care. These measures are mostly statistically significant (P
0.05). CONCLUSIONS: Over the three-year study period, specialty care was associ-
ated with significantly lower risk for relapses, fewer MS relapses, and longer re-
lapse-free time.
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OBJECTIVES: To estimate the prevalence of drug-treated MS within the Brazilian
public healthcare system (BPHS) and compare it with published prevalence rates.
METHODS: A previously described method to estimate the prevalence of diseases
treated with drugs that are specific to them and must be taken continuously was
employed. The total amount of MS drugs (Glatiramer 20mg, Betainterferon 22mcg,
Betainterferon 44mcg, Betainterferon 30mcg, Betainterferon 300mcg) dispensed
from 2006 to 2009 was obtained from the Ambulatory Information Database and
the daily doses defined by BPHS MS guidelines were used to convert it in drug-
treated cases. The drug-treated prevalence was compared with rates achieved
through conventional cross-sectional studies (4.27-15/100,000). Complementary
analysis was performed using Brazilian private health plans coverage data.
RESULTS: The estimated drug-treated prevalent cases within the BPHS were 3,569
in 2006 with a constant increasing until 2009 when reached 6,099. Drug-treated
prevalence rates (per 100,000) were 1.93, 2.63, 3.08, and 3.21 in 2006, 2007, 2008, and
2009, respectively. MS prevalent cases in the BPHS were estimated as ranging from
7,838 in 2006 to 8,113 in 2009 using the 4.27/100,000 rate and from 27,533 in 2006 to
28,499 in 2009 using the 15/100,000 rate. The prevalence of MS estimated from drug
consumption data was found to be 24.8-78.6% lower than that estimated from
cross-sectional studies. Even when private health plans coverage (
20%) was con-
sidered, the difference remained substantial between drug-treated and BPHS prev-
alent cases (total prevalent cases minus those supposed to have private coverage).
In 2009, this difference ranges from 310 (BPHS cases minus drug-treated cases)
to 22,399 (prevalent cases using 15/100,000 minus drug-treated). CONCLUSIONS:
These findings raise important questions about barriers to access to MS treatment,
undertreatment and/or underdiagnosis of MS and the reliability of the available
prevalence rates for use in projecting eligible population and performing budget
impact analysis.
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OBJECTIVES: To investigate the incidence of subarachnoid hemorrhage(SAH) in
patients with unruptured intracranial aneurysm(UIA) in South Korea from
2006-2009. METHODS: A longitudinal study using national representative health
claim database including all hospital records for every Korean citizen was em-
ployed. We identified patients with UIA who were 18-80 years old using ICD-10
codes of I67.1 in 2006. To select eligible patients, history period was applied for one
year from first diagnosis of UIA (i.e. index date) in 2006. We excluded patients with
UIA diagnosis, SAH, or treatments(clip and coil) during history periods. Patients
with head trauma or brain tumor during study periods were also excluded. Eligible
patients were followed for at least 3 years from index date. SAH patients were
defined as ICD-10 codes of I60 excluding I60.8 with the hospitalization of14days
or death within 14days from hospitalization. Sensitivity analysis was conducted to
see the robustness using different definition of SAH. Additionally, the length of stay
of SAH was estimated using generalized linear model with log link and gamma
distribution. RESULTS: We identified 7404 eligible patients with UIA, including
1,466(20%) treated patients and 5,938(80%) untreated patients formedian follow-up of
3.4 years. For patients with untreated UIA, the incidence rate of SAH was 0.7/100per-
son-years(PYs) (133/5,934 patients). In the definition of SAH of all hospitalization, the
incidence rate increased by 1.3/100PYs. The incidence of SAH was highest in the first
year after first diagnosis of UIA. Mean length of stay of SAH was 30days(95%CI:24.0-
36.2) formales and 38days(95%CI:32.8-42.8) for females, respectively.CONCLUSIONS:
The rupture rate for untreated UIA patients were 0.7-1.3/100 PY from 2006-2009.
This study results indicate that careful follow-up for UIA patients is needed to
prevent rupture and decrease economic burden of SAH.
PND9
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OBJECTIVES: To determine the effect of Alzheimer patient’s characteristics and
medications on their functional dependence to carry out activities of daily living
(ADL).METHODS: Data for the present study was obtained from National Nursing
Home Survey (NNHS-2004). Alzheimer patients selected using ICD9-CM code of
331.00. Patients aged above 65 with completed Minimum Data Set (MDS) assess-
ment were included in the study. Long formMDS-ADL scale ranging from 0-28 that
comprises sevenADLwas used for the study. Patientswho scored less than 15were
considered independent, while those who scored between15-28 were considered
dependent. Multivariate logistic regression was carried out to determine the effect
of patient demographics, geriatric conditions, co-morbidities and medication use
on functional dependence. Statistical analysis performed using SAS 9.1. RESULTS:
Among 166,382 Alzheimer patients, 61,094 (58.02%) were functionally dependent.
Being female (OR  1.743; 95%CI  1.131 - 2.685), presence of urinary incontinence
(OR  3.212; 95%CI  2.093 - 4.928), bowel incontinence (OR  6.384; 95% CI  4.318 -
9.439), presence of physical restraint (OR  1.960; 95% CI  1.367 - 2.809) and, poor
nutrition (OR2.015; 95%CI 1.447 - 2.806) significantly increased the risk of func-
tional dependence. Co-morbidities such as depression (OR 1.546; 95%CI 1.042 -
2.293) and osteoporosis (OR 1.644; 95%CI  1.054 - 2.562) increased the risk of
functional dependence while use of cholinesterase inhibitor (ChEI) decreased the
risk of functional dependence (OR  0.466; 95%CI  0.348 - 0.622). CONCLUSIONS:
Factors such as incontinence, poor nutrition, co-morbidities and physical restraint
use, in addition to cognitive impairment, significantly affect ability of Alzheimer
patients to carry out ADL. A multidimensional approach that controls these risk
factors may help decrease functional dependence in carrying out ADL.
Neurological Disorders – Cost Studies
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OBJECTIVES: To estimate the incremental budgetary change in per-member-per-
month (PMPM)medical and pharmacy costs after the introduction of everolimus, a
mammalian target of rapamycin inhibitor, for the treatment of subependymal gi-
ant-cell astrocytomas (SEGA) in patients with tuberous sclerosis complex. In a
phase I/II trial, everolimus was associated with reduced SEGA volume and seizure
frequency.METHODS: Two-year budget impact analysis was conducted based on a
retrospective, longitudinal study of administrative claims that showed an increase
in healthcare costs in the years leading up to and after surgery for SEGA removal.
Based on the aforementioned trial, themodel assumed that patients using everoli-
mus did not require surgical intervention; however, to be conservative, no impact
on seizure frequency was assumed. Estimates of SEGA prevalence, adverse events,
drug costs, and monitoring costs were based on published sources. Sensitivity
analysis evaluated the impact of estimating annual treatment costs for patients
with continuous eligibility only. RESULTS: In a hypothetical 1,000,000-member
health plan, an estimated 5.9 patients with growing SEGAs require care. Prior to
introducing everolimus, estimated total cost for the treatment of growing SEGAs
was $0.022 PMPM for all plan members. After introducing everolimus, there were
0.9, 19.8, and 6.6 fewer claims per patient for inpatient hospitalizations, outpatient
visits, and other pharmaceutical use, respectively. While pharmacy cost increased
by $0.038 PMPM, the total medical and pharmacy costs increased by only $0.026,
due to fewer SEGA surgeries. Sensitivity analysis showed greater savings in medi-
cal spending after the introduction of everolimus, resulting in a total spending
increase of $0.022 PMPM. CONCLUSIONS: Increased pharmaceutical spending in
the first two years of everolimus use was partially offset by savings in medical
costs. Potential additional savings in anti-epileptic drug spending may further off-
set the costs.
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OBJECTIVES: We determined the prevalence of OSA in patients with the specific
components of the metabolic syndrome (hypertension, hyperlipidemia and diabe-
tes). We also explored the incremental burden of OSA on health care utilization in
patientswith the specific components of themetabolic syndrome.METHODS:Data
were obtained from the Maryland Medicaid database for January 2001 through June
2006. These data contain all claims records for medical inpatient, outpatient, and
pharmacy services submitted to the state.We assigned beneficiaries into groups: hav-
ing any one of the components of the metabolic syndrome, to a cohort called “one
disease” (n7,086). Having any two of the three components the cohort called “two
diseases” (n6,774). Having all of the three components the cohort called “three dis-
eases” (n5,925). Medical utilization data were collected from the index date through
theendof the studyor the last dateof service,whichever occurredfirst.RESULTS:The
likelihood of getting OSA by disease cohort- Beneficiaries with any two compo-
nents of the metabolic syndrome or all three components had 2.10 and 3.24 times
respectively the likelihood of developing OSA compared to those with one compo-
nent alone. The average annualized medical utilization by OSA status in each
cohort, adjusted for age, gender, race, obesity, CCI scores, and number of days in
cohort. Beneficiaries who had the concomitant diagnosis of OSA had a significantly
higher number ofmedical services claims than thosewithout OSA; physician office
visits accounted for the largest share of medical utilization, followed by outpatient
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visits and inpatient care. The patternwas observed in each cohort. In two diseases:
sleep apnea- 29.6, no sleep apnea- 21.6. In three diseases: sleep apnea- 35.4, no
sleep apnea- 25.8. CONCLUSIONS: The more metabolic syndrome diseases the
higher risk for having OSA. The OSA burden is increasing the more metabolic
syndrome components exist.
PND12
LOWER DAILY AVERAGE CONSUMPTION AND GREATER PRESCRIPTION COST
SAVINGS OF ARMODAFINIL COMPARED WITH MODAFINIL: A 12-MONTH
RETROSPECTIVE DATABASE ANALYSIS
Carlton R1, Regan TS1, Rice G2
1Xcenda, LLC., Palm Harbor, FL, USA, 2ITSRx, Houston, TX, USA
OBJECTIVES: Armodafinil and modafinil are indicated to improve wakefulness in
patientswith excessive sleepiness associatedwith treated obstructive sleep apnea,
shift work disorder, and narcolepsy. Because both medications are approved for
once-daily dosing with different tablet strengths, their real-world utilization may
differ. This analysis examined utilization of armodafinil and modafinil based on
daily average consumption (DACON) and determined the impact of armodafinil
and modafinil on pharmacy budgets using an economic modeling technique.
METHODS: DACON was examined in a retrospective database analysis of Wolt-
ers Kluwer Source LX pharmacy analytic data collected from March 1, 2009 to
May 31, 2010. DACON was calculated by dividing the total tablets dispensed by
the total days supplied. An economic model was used to evaluate the financial
impact of changes in prescription share from modafinil to armodafinil.
RESULTS: The DACON for armodafinil and modafinil were 1.03 (70,976 prescrip-
tions) and 1.40 (453,216 prescriptions), respectively. Among patients with 2 to 8
prescription fills for armodafinil, the DACON remained between 1.03 and 1.05. A
total of 6,069 modafinil patients switched to armodafinil. Their DACON on
modafinil was 1.46 before switching and was 1.05 after switching to armodafinil.
Based on economic modeling, and assuming a 10% increase in armodafinil’s share
of prescriptions, the projected annual cost savings with armodafinil would be
$921,949 (per-member-per-month savings of $0.077). Assuming a 20% increase in
armodafinil’s share, the projected annual savings would be $1,843,897 (per-mem-
ber-per-month savings of $0.154). CONCLUSIONS: By using pharmaceutical claims
data in tandem with well-designed economic models, payers can better estimate
current and future pharmaceutical spending. Based on this DACON analysis, the
utilization of armodafinil has a real-world advantage over modafinil that can sig-
nificantly affect pharmacy budgets. This researchwas sponsored by and conducted
in collaboration with Cephalon, Inc., Frazer, PA.
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OBJECTIVES: The objective of this retrospective claims database study was to bet-
ter understand the burden of illness for pediatric patients in the US who have
epilepsy with partial onset seizures and who are being treated with anti-epileptic
drugs (AEDs).METHODS:Datawere administrative claims from a large national US
health plan. Patients were commercial enrollees 2 years and 17 years of age
with 1 pharmacy claim for an oral AED from1/1/2006 – 11/30/2008; index datewas
defined as the first AED claim. Patients also had  1 medical claim for epilepsy
(ICD-9-CM 345.xx) during the 6 months pre-index period and were continuously
enrolled 12 months post-index. RESULTS: Within commercially insured pediatric
patients, 3,889 childrenmet inclusion criteria; 54%weremales; 59%were aged 2-11
years; and 51% lived in the southern US. Themean age of the population was 10.08
years. Overall, 77% had a Quan-Charlson comorbidity score of zero. Most fre-
quently reported AHRQ comorbid conditions included epilepsy convulsions (100%),
respiratory infections (66%), other nervous system disorders (43%) and headache
(20%). Of 8 epilepsy-related risk factors examined patients experienced hyperki-
netic syndrome (10%) and developmental disabilities (20%). Of 17 AEDmedications
examined, the most prescribed overall were: oxcarbazepine (OXC) 21%; levetirac-
etam (LEV) 19%; valporate (VPA) 17%; lamotrigine (LTG) 17%; with least prescribed
being gabapentin (GBP) at 1%. Their respective mean annual post-index pharmacy
and total costs were: $5441 and $11,430, LTG; $3025 and $9121, LEV; $2095 and
$5556, OXC; $1308 and $2807, VPA; and $917 and $1597, GBP. The overall post-index
mean annual pharmacy costs were $2637 andmean annual total costs were $6813.
CONCLUSIONS:Comorbid conditions associatedwith epilepsy are likely to contrib-
ute to the costs of pediatric epilepsy. Lamotrigine and Levetiracetam had the high-
est annual pharmacy costs compared to other drugs.
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OBJECTIVES: The objective of this retrospective claims database study was to bet-
ter understand the burden of illness for adults in the US who have epilepsy with
partial onset seizures and who are being treated with anti-epileptic drugs (AEDs).
METHODS: Data were administrative claims from a large national US health plan.
Patients were commercial enrollees18 years with 1 pharmacy claim for an oral
AED from 1/1/2006 – 11/30/2008; index date was defined as the first AED claim.
Patients also had  1 medical claim for epilepsy (ICD-9-CM 345.xx) during the 6
months pre-index period and were continuously enrolled 12 months post-index.
RESULTS:Within commercially insured adult patients, 9,889 adults met the study
inclusion criteria; 45%weremales; themean age was 43 years; and 49% lived in the
southern region of the US. Overall, 67% had a Quan-Charlson comorbidity score of
zero. Most frequently reported AHRQ comorbid conditions included: epilepsy con-
vulsions (100%), respiratory infections (42%), heart disease (36%) and headache
(31%). Of 8 epilepsy-related risk factors examined, patients most experienced de-
pression/mood disorders (12%), anxiety (8%), migraine (8%) and sleep disorders
(8%). Of 17 AED medications examined, the most prescribed overall were: leveti-
racetam (LEV) 19%; lamotrigine (LTG) 18%; phenytoin (PHT) 18%; carbamazepine
(CBZ) 14%, with the least prescribed being phenobarbital (PB) at 2%. Their respec-
tivemean annual post-index pharmacy and total costs were: $5169 and $6806, LTG;
$3788 and $6866, LEV; $1609 and $2564, CBZ; $1011 and $2409, PHT; and $245 and
$451, PB. The overall post-index mean annual pharmacy costs were $2736, and the
mean annual total costs were $4390. CONCLUSIONS: Epilepsy is a relatively com-
monneurological disorder associatedwith a range of comorbidities that impact the
medical management and the economic burden related to the disease.
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OBJECTIVES: Estimate the incremental costs associated with Alzheimer’s Disease
(AD). The incremental impact of AD on Medicaid costs has not been updated since
1995 and the impact of AD on other payers is unclear.METHODS: Patients age 50
were identified from de-identified Medicaid paid claims from California [MediCal].
All patients were MediCal eligible for the period 2004-2006 [survivors]. Data in-
cluded information on payments by MediCal, Medicare and other payers. AD pa-
tients had at least one AD diagnosis. A 20% random sample of non-AD patients was
selected and a matched control group was identified using propensity score meth-
ods. Health care cost and resource utilization were measured annually during the
2004-2006 period broken down by type of service and payer. Multivariate statistical
models were estimated to document the incremental impact of AD controlling for
baseline characteristics of the matched AD and non-AD patients. RESULTS: The
incremental cost of AD relative to non-AD patients increased from$7,217 in 2004
to$15,563 in 2006, totaling$34,745 over 3 years. Themajority of the cost burden
is bourn by MediCal [$30,090] primarily for nursing home care [$15,498], home
health care [$9,146] and prescription drugs [$3,938]. The incremental cost of AD
on Medicare and other payers [including out-of-pocket costs] were $2,814 and
$1,842, respectively [p0.0001 for all estimates].CONCLUSIONS:The incremental
impact of AD on the health care system is significant. The increased costs attrib-
uted to AD in this analysis are due primarily to higher costs for nursing home care
and home health services. New AD medications currently under development, if
effective, will benefit Medicaid programs but be paid for largely by Medicare under
Part D. This study provides useful information on the potential benefits that could
accrue due to an effective AD treatment and documents how these benefits will be
distributed by payer.
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OBJECTIVES: To examine hemophilia-related healthcare costs among persons
with hemophilia A at six US Hemophilia Treatment Centers (HTCs). METHODS:
Data on 315 persons aged 2-65 years from seven states enrolled in Hemophilia
Utilization Group Study (HUGS-Va, 2005-2007) were obtained prospectively from
interviews and chart reviews. One-year healthcare utilization data (HTC visits,
laboratory tests, outpatient visits, emergency room (ER) visits, hospitalizations)
and units of clotting factor dispensed were used to impute costs. HTC visit and
laboratory test expenditures were obtained from Medicare payment schedules.
Inpatient costs were estimated using ICD-9 codes and HCUP National Inpatient
Sample charges adjusted for cost-to-charge ratio from MedPAR. ER costs were es-
timated using MEPS data. Factor costs were estimated using Medicare Part B reim-
bursement rates. Per-unit prices for non-factor medications were estimated using
wholesale acquisition costs. All costs were converted to 2010 US dollars. Socio-
demographic and clinical characteristics associated with higher costs were ana-
lyzed using a multivariate model. RESULTS: Fifty-one percent of participants were
adults; mean age was 21.2(14.8) years. Two-thirds had severe hemophilia. 94%
used clotting factor; 64% of severe patients infused prophylactically. Annual mean
healthcare costs per patient (excluding medication) were $3,912(9,267),
$3,975(8,422), $16,185(46,097) and $2,852(7,721), respectively, for patients with
mild,moderate, severe hemophilia on episodic treatment, or severe hemophilia on
prophylactic treatment. Annual hemophilia-relatedmedication costs for the same
groupswere $42,377(115,246,median:$3,573), $63,063(113,571,median:$22,587),
$159,830(143,220,median:$113,263) and $275,376(178,573,median:$246,333), re-
spectively (P0.0001). Inhibitor patients (N16) had healthcare and medication
costs of $13,086(19,163,median:$2,223) and $721,603(914,069,median:$199,319),
respectively. Older age, higher weight, greater hemophilic severity, with insurance
coverage, prophylaxis treatment, and positive inhibitor were associated with
higher total costs. CONCLUSIONS: Hemophilia is a costly disorder. This data pro-
vides information on annual healthcare and factor costs associated with hemo-
philia. Identifying factors associatedwith increased healthcare utilization and out-
comes will advance our understanding of the economic impact of this condition.
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